Early in the pandemic, a team of researchers from across six universities and three countries came together to investigate the RNA helicase (non-structural protein 13, NSP13) of the SARS-CoV-2 virus1. NSP13 is critical to the replication of the virus, making it a promising target for anti-viral drug therapies. HECBioSim provided technical support and compute time on the UK’s Tier 1 supercomputer ARCHER to the project. The team reported some valuable insights, including the location and structure of key “pockets” into which substrates (potentially, inhibiting substrates) can bind. This work helped to advance the dialogue on suitable drug targets for SARS-CoV-2. Find out more by engaging with the interactive presentation below!
1) D. Berta , M. Badaoui , S. A. Martino , P. J. Buigues , A. V. Pisliakov , N. Elghobashi-Meinhardt , G. Wells , S. A. Harris , E. Frezza and E. Rosta , Chem. Sci., 2021, 12 , 13492 —13505 https://doi.org/10.1039/D1SC02775A
This interactive presentation showcases research done on the RNA helicase protein. We recommend it be viewed in full screen mode for the best experience!